Public research summary

MRNA Stock Analysis: Moderna Inc

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine

Data through Sep 8, 2026
Latest close
$192.57
20-day change
+24.83%
Trend state
BULLISH
Classification
Healthcare · Biotechnology

Market context

Moderna Inc moved +24.83% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.

Latest report

The latest cached company filing period (FY2025 · $1.9B revenue · -$2.8B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.

Six-dimension read

Health is currently the strongest dimension at 4.6/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.

Value 1.0/6
Growth 1.5/6
Quality 1.3/6
Profitability 0.5/6
Health 4.6/6
Future 2.6/6
Built from cached market data, company filings and transparent rule-based calculations. Automated research is informational and is not investment advice.

Loading the interactive report and checking your access…